Leidos to participate in the Goldman Sachs Industrials and Materials Conference

Rhea-AI Summary

Lunit (KRX:328130.KQ) and Agilent (NYSE:A) announced a nonexclusive collaboration on Sept 22, 2025 to co-develop AI-powered companion diagnostic (CDx) solutions for complex biomarker assays.

The partnership will combine Lunit's AI algorithms and Agilent's tissue-based diagnostic assays, initially targeting research and clinical-trial use to improve biomarker accuracy and support pharma CDx development. Lunit noted its FDA-cleared Lunit INSIGHT suite is used at over 7,000 medical institutions in more than 65 countries.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Live audio webcast available on Dec. 3, 2025, from 12:10 p.m. to 12:45 p.m. ET

RESTON, Va., Nov. 18, 2025 /PRNewswire/ -- Leidos (NYSE: LDOS) today announced it will participate in the Goldman Sachs Industrials and Materials Conference being held in New York City.

Chris Cage, chief financial officer, will engage in a question and answer "fireside chat" on Wednesday, Dec. 3, 2025, at 12:10 p.m. ET.  

A live audio webcast of the event will be available on the Leidos Investor Relations website at http://ir.leidos.com.  A replay of the webcast will be available following the presentation at the same link listed above for 30 days afterward.

About Leidos
Leidos is an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations. Headquartered in Reston, Virginia, with 47,000 global employees, Leidos reported annual revenues of approximately $16.7 billion for the fiscal year ended January 3, 2025. For more information, visit www.leidos.com.

CONTACTS:
Media contact:	Investor Relations:
Brandon Ver Velde	Stuart Davis
571.926.1627	571.526.6124
brandon.p.vervelde@leidos.com	ir@leidos.com

 

FAQ

What did Lunit and Agilent announce on Sept 22, 2025 regarding companion diagnostics?

They announced a nonexclusive collaboration to co-develop AI-powered companion diagnostic solutions for complex biomarker assays, focusing on research and clinical trials.

How will the Lunit–Agilent collaboration affect biomarker testing for pharma (KRX:328130.KQ, NYSE:A)?

The collaboration aims to combine Lunit AI with Agilent tissue assays to improve diagnostic accuracy and support pharma companion diagnostic development.

What is the initial focus and timeline for Lunit and Agilent's CDx work?

The initial focus is on co-developing AI-powered assays for use in research and clinical trials; no commercial launch timeline was disclosed.

Does the announcement disclose financial terms or commitments for Lunit (KRX:328130.KQ) or Agilent (NYSE:A)?

No. The announcement describes a nonexclusive collaboration but does not provide financial terms, deal value, or binding commercial amounts.

What existing Lunit assets are cited as relevant to the collaboration with Agilent (NYSE:A)?

Lunit cited its FDA-cleared Lunit INSIGHT suite used at over 7,000 medical institutions in more than 65 countries and its biomarker-focused Lunit SCOPE platform.